AACR21: new CAR-T therapy shows promise in B-cell lymphoma

Written by Rachel Jenkins, Future Science Group

New CAR-T therapy

A new trial has released early results investigating a pioneering CAR-T immunotherapy. The research is being led by colleagues at the UCLA Jonsson Comprehensive Cancer Center (CA, USA), who found that using a bilateral attack helps to minimize treatment resistance. This results in long-lasting remission for people with non-Hodgkin’s B-cell lymphoma that has come back or not responded to treatment. The novel approach recognizes two targets expressed on B-cell lymphoma, CD19 and CD20, simultaneously, and will be presented at the American Association for Cancer Research Annual Meeting (AACR; 9–14 April 2021). A total of five patients enrolled in the small...

To view this content, please register now for access

It's completely free